AA
MBX

ALPS Advisors’s MBX Biosciences MBX Stock Holding History

ALPS Advisors’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.09M Sell
36,550
-322
-0.9% -$10.9K 0.01% 574
2025
Q4 		$1.16M Buy
36,872
+20,032
+119% +$486K 0.01% 509
2025
Q3 		$295K Sell
16,840
-1,208
-7% -$16.2K ﹤0.01% 988
2025
Q2 		$206K Sell
18,048
-7,986
-31% -$81.4K ﹤0.01% 1004
2025
Q1 		$192K Sell
26,034
-986
-4% -$10.4K ﹤0.01% 963
2024
Q4 		$498K Buy
+27,020
New +$576K ﹤0.01% 604

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

ALPS Advisors's MBX Position: Q1 2026 in Review

ALPS Advisors reduced its MBX Biosciences (MBX) stake by 0.87% in Q1 2026, selling an estimated $10.9K and leaving 36,550 shares worth $1.09M. The position accounts for 0.01% of the portfolio, ranked #574.

ALPS Advisors first reported a position in MBX in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.16M in Q4 2025. 157 funds tracked by Wall St. Rank hold MBX as of Q1 2026.

  • ALPS Advisors held 36,550 shares of MBX Biosciences worth $1.09M as of Q1 2026.
  • ALPS Advisors sold 322 MBX Biosciences shares in Q1 2026, an estimated $10.9K.
  • MBX Biosciences made up 0.01% of ALPS Advisors's portfolio in Q1 2026, its #574 holding.
  • ALPS Advisors first reported a position in MBX Biosciences in Q4 2024 and has held it in 6 quarters since.
  • ALPS Advisors's MBX Biosciences position peaked at $1.16M in Q4 2025.
  • 157 funds tracked by Wall St. Rank held MBX Biosciences as of Q1 2026.

Based on ALPS Advisors's 13F filing for Q1 2026, filed 8 May 2026.